Topic
The latest Gene Therapy news and analysis from Tech Arcade.
The FDA just approved FAYUVI, the first-ever treatment for Sanfilippo syndrome type A: a one-time gene therapy from Ultragenyx priced at $3.95 million per patient.
Ultragenyx's Fayuvi is the first-ever treatment for Sanfilippo syndrome type A — a one-time gene therapy priced at $3.95 million.
The FDA approved Ultragenyx's Fayuvi, the first-ever treatment for Sanfilippo syndrome type A, a fatal childhood brain disease with zero prior options. The one-time gene therapy lists at $3.95 million.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
The FDA approved GENGLYCOS, Ultragenyx's first gene therapy and the first treatment for the root cause of glycogen storage disease type Ia. The headline result: 31% less daily cornstarch.
